摘要
Objective To evaluate the relationship of p53 alteration and myc family gene overexpression with the clinical characteristics of lung cancer. Methods A series of 59 resected primary lung cancer specimens was analyzed for p53 gene by DNA/PCR sequencing and immunohistochemistry technique, and for myc family genes by RT PCR methods. Results Thirty seven of 57 tumors were found to have p53 mutations or/and p53 protein accumulation. The presence of p53 alteration was not related to tumor size, lymph node metastasis, stage and relapse. Forty seven cases were analyzed for myc family genes. The results showed that there was a positive correlation between unregulative expression of myc genes and the above mentioned clinical parameters. Our finding also showed that 19 of 30 cases (63%) with p53 alteration had myc gene overexpression which occurred in 63% and 76% cases with stage Ⅲ and relapse, respectively, which was higher than 27% and 22% with p53 alteration but no myc gene overexpression and 50% and 71% with p53 negative but myc gene overexpression. Conclusions p53 alteration is a vital genetic event in the earlier stage of lung carcinogenisis, but not a prognostic marker. myc family genes overexpression may be regarded as one of the independant prognostic determinants in lung cancer. The cooperation between p53 alteration and myc gene overexpression may occur during progression of lung cancer, but prognostic determinant is myc gene overexpression.
Objective To evaluate the relationship of p53 alteration and myc family gene overexpression with the clinical characteristics of lung cancer. Methods A series of 59 resected primary lung cancer specimens was analyzed for p53 gene by DNA/PCR sequencing and immunohistochemistry technique, and for myc family genes by RT PCR methods. Results Thirty seven of 57 tumors were found to have p53 mutations or/and p53 protein accumulation. The presence of p53 alteration was not related to tumor size, lymph node metastasis, stage and relapse. Forty seven cases were analyzed for myc family genes. The results showed that there was a positive correlation between unregulative expression of myc genes and the above mentioned clinical parameters. Our finding also showed that 19 of 30 cases (63%) with p53 alteration had myc gene overexpression which occurred in 63% and 76% cases with stage Ⅲ and relapse, respectively, which was higher than 27% and 22% with p53 alteration but no myc gene overexpression and 50% and 71% with p53 negative but myc gene overexpression. Conclusions p53 alteration is a vital genetic event in the earlier stage of lung carcinogenisis, but not a prognostic marker. myc family genes overexpression may be regarded as one of the independant prognostic determinants in lung cancer. The cooperation between p53 alteration and myc gene overexpression may occur during progression of lung cancer, but prognostic determinant is myc gene overexpression.
